Skin vasodilator effect of exogenous urotensin‐II in hypertensives not exposed to antihypertensive medication

To investigate the effect of urotensin‐II (U‐II) on skin vascular tone in normotensive subjects and in patients with essential arterial hypertension (EHT), forearm skin blood flux and skin blood flowmotion (SBF) response to U‐II cathodal iontophoresis was investigated using laser Doppler flowmetry (LDF) and spectral Fourier analysis in 10 young normotensive subjects, before and after intra‐dermal injection of the nitric oxide synthetase inhibitor NG‐monometil‐l‐arginine (L‐NMMA). Forearm skin blood flux response to U‐II cathodal iontophoresis was also investigated using LDF in 15 newly diagnosed EHT patients, in 15 long‐standing EHT patients and in 15 age‐ and sex‐matched normotensive subjects. Intra‐dermal injection of L‐NMMA significantly blunted the increase in skin blood flux (from 342.5±153.0% to 193.5±78.9%, p<0.05) and completely inhibited the increase in spectral amplitude of 0.009–1.6 Hz total‐spectrum SBF, as well as of the 0.009–0.02 Hz component, related to endothelial activity, which occurred following U‐II iontophoresis in normotensive subjects. A significant increase in skin blood flux compared with baseline was also induced by U‐II iontophoresis in newly diagnosed (354±195% change from baseline) and long‐standing patient (324±180% change from baseline), without significant difference with normotensive subjects (400±251% change from baseline). These findings demonstrate that: (i) U‐II exerts a skin vasodilator effect in normotensive subjects, which is partly endothelial‐dependent; (ii) U‐II skin vasodilator effect is preserved in newly diagnosed and in long‐standing EHT patients.

[1]  C. Di Maria,et al.  Skin microcirculatory effect of exogenous calcitonin gene-related peptide (CGRP) evaluated by laser Doppler flowmetry coupled with iontophoresis in healthy subjects. , 2007, Microvascular research.

[2]  L. Ghiadoni,et al.  Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. , 2006, Journal of the American College of Cardiology.

[3]  H. Krum,et al.  Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. , 2005, American journal of hypertension.

[4]  A. Carpi,et al.  Skin blood flowmotion response to insulin iontophoresis in normal subjects. , 2005, Microvascular research.

[5]  B. Cheung,et al.  Urotensin II: Its Function in Health and Its Role in Disease , 2005, Cardiovascular Drugs and Therapy.

[6]  B. Cheung,et al.  Plasma concentration of urotensin II is raised in hypertension , 2004, Journal of hypertension.

[7]  H. Krum,et al.  Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure , 2004, Circulation.

[8]  H. Krum,et al.  Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. , 2004, Current opinion in investigational drugs.

[9]  A. Davenport,et al.  Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. , 2002, Canadian journal of physiology and pharmacology.

[10]  J. Pernow,et al.  Urotensin II evokes potent vasoconstriction in humans in vivo , 2002, British journal of pharmacology.

[11]  E. Kostenis,et al.  Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  M. Shichiri,et al.  Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues , 2001, Journal of hypertension.

[13]  A. Davenport,et al.  Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats , 2001, British journal of pharmacology.

[14]  J. McMurray,et al.  Effects of Urotensin II in Human Arteries and Veins of Varying Caliber , 2001, Circulation.

[15]  S. Douglas,et al.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. , 2001, American journal of physiology. Heart and circulatory physiology.

[16]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[17]  A. Stefanovska,et al.  Wavelet analysis of oscillations in the peripheral blood circulation measured by laser Doppler technique , 1999, IEEE Transactions on Biomedical Engineering.

[18]  L. Ghiadoni,et al.  Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. , 1999, Circulation.

[19]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[20]  A Stefanovska,et al.  Oscillations in the human cutaneous blood perfusion signal modified by endothelium-dependent and endothelium-independent vasodilators. , 1999, Microvascular research.

[21]  L. Ghiadoni,et al.  Cutaneous vasodilation to acetylcholine in patients with essential hypertension. , 1997, Journal of cardiovascular pharmacology.

[22]  M Intaglietta,et al.  Microvascular vasomotion: origin of laser Doppler flux motion. , 1994, International journal of microcirculation, clinical and experimental.

[23]  A. Salvetti,et al.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension. , 1993, Hypertension.

[24]  M Intaglietta,et al.  Quantitation of rhythmic diameter changes in arterial microcirculation. , 1984, The American journal of physiology.